Pierre Fabre amends license agreement with Puma Biotechnology
Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
European circular bioeconomy fund near closing
The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the 250m EU circular bioeconomy fund.
Researchers find new indication for cancer drug
French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Research team improves safety of LGMD2A gene therapy
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
GeNeuro and Karolinska Institute collaborate in multiple sclerosis
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Tecentriq-Avastin combo hits endpoint in liver cancer
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics bags 37.3m in Series B financing round
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (34.4m).
GHO capital launches EU’s largest fund ever for life sciences
GHO Capital raises 975m in largest ever European private equity healthcare fund.
Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Novo secures Dicernas RNAi liver assets
Danish Novo Nordisk A/S has secured access to Dicerna Incs GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.